Amgen (WBO:AMGN) EV-to-Revenue : 7.08 (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Amgen EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amgen's enterprise value is €185,018 Mil. Amgen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €26,134 Mil. Therefore, Amgen's EV-to-Revenue for today is 7.08.

The historical rank and industry rank for Amgen's EV-to-Revenue or its related term are showing as below:

WBO:AMGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.33 Med: 5.78 Max: 8.07
Current: 7.04

During the past 13 years, the highest EV-to-Revenue of Amgen was 8.07. The lowest was 4.33. And the median was 5.78.

WBO:AMGN's EV-to-Revenue is ranked worse than
83.72% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs WBO:AMGN: 7.04

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), Amgen's stock price is €252.45. Amgen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €48.60. Therefore, Amgen's PS Ratio for today is 5.19.

Amgen EV-to-Revenue Historical Data

The historical data trend for Amgen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen EV-to-Revenue Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

7.00

6.11

5.81

6.45

7.37

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															6.45	6.08	5.49	6.32	7.37

Competitive Comparison of Amgen's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Amgen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amgen's EV-to-Revenue falls into.

Amgen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Amgen's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	185017.787	/	26133.991
	=	7.08

Amgen's current Enterprise Value is €185,018 Mil.
Amgen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €26,134 Mil.

Amgen (WBO:AMGN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Amgen's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	252.45	/	48.6
	=	5.19

Amgen's share price for today is €252.45.
Amgen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €48.60.

Amgen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amgen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (WBO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.